Combinaisons de thérapies anti-HER2: deux balles pour une même cible !GONCALVES, Anthony.Bulletin du cancer. 2012, Vol 99, Num 9, pp 813-814, issn 0007-4551, 2 p.Article

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing : Biologic and Methodologic ConsiderationsSAUTER, Guido; LEE, James; BARTLETT, John M. S et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1323-1333, issn 0732-183X, 11 p.Article

Reliability of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry in Breast Core Needle BiopsiesLEBEAU, Annette; TURZYNSKI, Andreas; THOMSSEN, Christoph et al.Journal of clinical oncology. 2010, Vol 28, Num 20, pp 3264-3270, issn 0732-183X, 7 p.Article

Radionuclide therapy of HER2-positive microxenografts using a ¹⁷⁷Lu-labeled HER2-specific affibody moleculeTOLMACHEV, Vladimir; ORLOVA, Anna; WENNBORG, Anders et al.Cancer research (Baltimore). 2007, Vol 67, Num 6, pp 2773-2782, issn 0008-5472, 10 p.Article

Surexpression de HER2: un dictat ? = Overexpression of HER2: a dictat?COTTU, P.Société Française de Sénologie et de Pathologie Mammaire. Journées. 2011, pp 168-173, isbn 978-2-8178-0248-0, 1Vol, 6 p.Conference Paper

Targeting HER2 epitopesSUMANTA KUMAR PAL; PEGRAM, Mark.Seminars in oncology. 2006, Vol 33, Num 4, pp 386-391, issn 0093-7754, 6 p.Article

Two Dimensions in Targeting HER2MOASSER, Mark M.Journal of clinical oncology. 2014, Vol 32, Num 19, pp 2074-2077, issn 0732-183X, 4 p.Article

ErbB2 Trafificking and Degradation Associated with K48 and K63 PolyubiquitinationMARX, Corina; HELD, Jason M; GIBSON, Bradford W et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 9, pp 3709-3717, issn 0008-5472, 9 p.Article

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 FunctionGARRETT, Joan T; SUTTON, Cammie R; GABRIELA KUBA, Maria et al.Clinical cancer research (Print). 2013, Vol 19, Num 3, pp 610-619, issn 1078-0432, 10 p.Article

Radiation- and anthracycline-induced cardiac toxicity and the influence of ErbB2 blocking agentsSEEMANN, Ingar; TE POELE, Johannes A. M; SONG, Ji-Ying et al.Breast cancer research and treatment. 2013, Vol 141, Num 3, pp 385-395, issn 0167-6806, 11 p.Article

PGC-1α Promotes the Growth of ErbB2/Neu―Induced Mammary Tumors by Regulating Nutrient SupplyKLIMCAKOVA, Eva; CHENARD, Valérie; MCGUIRK, Shawn et al.Cancer research (Chicago, Ill.). 2012, Vol 72, Num 6, pp 1538-1546, issn 0008-5472, 9 p.Article

HER2 Overexpression Elicits a Proinflammatory IL-6 Autocrine Signaling Loop That Is Critical for TumorigenesisHARTMAN, Zachary C; YANG, Xiao-Yi; GLASS, Oliver et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 13, pp 4380-4391, issn 0008-5472, 12 p.Article

Mechanisms of Resistance to HER2 Target TherapyTORTORA, Giampaolo.Journal of the National Cancer Institute. Monographs. 2011, Vol 43, pp 95-98, issn 1052-6773, 4 p.Conference Paper

HER-2 amplification is highly homogenous in gastric cancerBILOUS, Michael; OSAMURA, Robert Y; RÜSCHOFF, J et al.Human pathology. 2010, Vol 41, Num 2, pp 304-305, issn 0046-8177, 2 p.Article

PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: Specific skipping of erbB-2 exon 19 coding for the ATP catalytic domainPANKRATOVA, Stanislava; NIELSEN, Birgit N; SHIRAISHI, Takehiko et al.International journal of oncology. 2010, Vol 36, Num 1, pp 29-38, issn 1019-6439, 10 p.Article

Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL : a monocentric study of 44 casesCHEVALLIER, P; ROBILLARD, N; HOUILLE, G et al.Leukemia. 2009, Vol 23, Num 4, pp 806-807, issn 0887-6924, 2 p.Article

Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic MiceRADKEVICH-BROWN, Olga; JACOB, Jennifer; KERSHAW, Michael et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 1, pp 212-218, issn 0008-5472, 7 p.Article

Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer CellsMILLER, Todd W; FORBES, James T; COOK, Rebecca S et al.Clinical cancer research (Print). 2009, Vol 15, Num 23, pp 7266-7276, issn 1078-0432, 11 p.Article

External quality assurance of HER2 fluorescence in situ hybridisation testing : Results of a UK NEQAS pilot schemeBARTLETT, John M. S; IBRAHIM, Merdol; JASANI, Bharat et al.Journal of clinical pathology. 2007, Vol 60, Num 7, pp 816-819, issn 0021-9746, 4 p.Article

First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumorsMUNSTER, Pamela N; BRITTEN, Carolyn D; TOLCHER, Anthony W et al.Clinical cancer research. 2007, Vol 13, Num 4, pp 1238-1245, issn 1078-0432, 8 p.Article

HER2 testing in the UK : consensus from a national consultationDOWSETT, M; HANBY, A. M; LAING, R et al.Journal of clinical pathology. 2007, Vol 60, Num 6, pp 685-689, issn 0021-9746, 5 p.Article

Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practiceDOLAN, Michelle; SNOVER, Dale.American journal of clinical pathology. 2005, Vol 123, Num 5, pp 766-770, issn 0002-9173, 5 p.Article

Role of Herceptin® in primary breast cancer: Views from North America and europeLEYLAND-JONES, Brian; SMITH, Ian.Oncology. 2001, Vol 61, pp 83-91, issn 0030-2414, SUP2Conference Paper

Activated ERBB2/HER2 Licenses Sensitivity to Apoptosis upon Endoplasmic Reticulum Stress through a PERK-Dependent PathwayMARTIN-PEREZ, Rosa; PALACIOS, Carmen; YERBES, Rosario et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 6, pp 1766-1777, issn 0008-5472, 12 p.Article

Targeting P13K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKTO'BRIEN, Neil A; MCDONALD, Karen; FINN, Richard S et al.Clinical cancer research (Print). 2014, Vol 20, Num 13, pp 3507-3520, issn 1078-0432, 14 p.Article